Vitamin B2-sensitised photooxidation of the ophthalmic drugs Timolol and Pindolol: kinetics and mechanism

Author： Criado Susana   García Norman A.  

Publisher： Maney Publishing

ISSN： 1743-2928

Source： Redox Report, Vol.9, Iss.5, 2004-10, pp. : 291-297

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Topical Dorzolamide 2%/Timolol 0.5% Ophthalmic Solution: A Review of its Use in the Treatment of Glaucoma and Ocular Hypertension

By Frampton James E.   Perry Caroline M.  

Drugs & Aging, Vol. 23, Iss. 12, 2006-01 ,pp. : 977-995

Adis International

Access to resources Recommend Favorite

Emerging drugs for ophthalmic diseases

By Novack Gary D  

Expert Opinion on Emerging Drugs, Vol. 8, Iss. 1, 2003-05 ,pp. : 251-266

Informa Healthcare

Access to resources Recommend Favorite

Timolol: Syncope following ophthalmic administration in elderly patients: 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1099, 2006-01 ,pp. : 17-18

Adis International

Access to resources Recommend Favorite

Timolol: Allergic contact dermatitis following ophthalmic administration: case report

By  

Reactions Weekly, Vol. 1, Iss. 1239, 2009-01 ,pp. : 32-32

Adis International

Access to resources Recommend Favorite

Topical Brimonidine 0.2%/Timolol 0.5% Ophthalmic Solution: In Glaucoma and Ocular Hypertension

By Frampton James E.  

Drugs & Aging, Vol. 23, Iss. 9, 2006-01 ,pp. : 753-761

Adis International

Access to resources Recommend Favorite